Menu Search
Equities

Jacobio Pharmaceuticals Group Co Ltd

1167:HKG.HZ

Jacobio Pharmaceuticals Group Co Ltd

Actions
  • Price (HKD)1.87
  • Today's Change0.02 / 1.08%
  • Shares traded1.10m
  • 1 Year change-73.21%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.

  • Revenue in HKD (TTM)68.72m
  • Net income in HKD-388.50m
  • Incorporated2018
  • Employees301.00
  • Location
    Jacobio Pharmaceuticals Group Co LtdBuilding F2, No. 88Kechuang 6th Street, Beijing EconomicTechnological Development AreaBEIJING ChinaCHN
  • Phone+86 1 056315466
  • Fax+86 1 056315314
  • Websitehttp://www.jacobiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.